KIMBERLY PETERS: Open Payments
NPI 1942758370 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 22 payments from 14 companies in 2025. Trend: 2023 $366 · 2024 $504 · 2025 $899
Food & beverage: $799Education: $100
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 2 | $225 |
| Genmab U.S., Inc. | 1 | $125 |
| Gilead Sciences, Inc. | 3 | $96 |
| Janssen Biotech, Inc. | 3 | $95 |
| EMD Serono, Inc. | 2 | $64 |
| Amgen Inc. | 2 | $62 |
| PFIZER INC. | 2 | $50 |
| Pharmacosmos Therapeutics Inc. | 1 | $30 |
| GlaxoSmithKline, LLC. | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
Products named: Jakafi, Tivdak, Trodelvy, RYBREVANT, IMDELLTRA (AMG757), MONOFERRIC, LUMAKRAS, OJJAARA.
Industry payments across MO — which companies pay providers there.
